We extended the analysis to two independent patient-derived RAS/BRAF wt cetuximab-sensitive CRC organoids (IRCC-10C and CRC0078) and challenged them with the same treatments previously used in the 2D assays. The gene discussed is BRAF; the disease is colorectal carcinoma.